Human Genome Epidemiology Literature Finder
|
Records 1 - 23 (of 23 Records) |
| Query Trace: Melanoma and MUT[original query] |
|---|
| BRAF mutations in advanced cancers: clinical characteristics and outcomes. PloS one 2011 6 (10): e25806. El-Osta Hazem, Falchook Gerald, Tsimberidou Apostolia, Hong David, Naing Aung, Kim Kevin, Wen Sijin, Janku Filip, Kurzrock Razel |
| Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases. Journal of the National Cancer Institute 2016 Nov 108 (11): . Helgadottir Hildur, Höiom Veronica, Tuominen Rainer, Nielsen Kari, Jönsson Göran, Olsson Håkan, Hansson Joh |
| Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. Journal of gastrointestinal oncology 2018 Aug 9 (4): 610-617. Fabrizio David A, George Thomas J, Dunne Richard F, Frampton Garrett, Sun James, Gowen Kyle, Kennedy Mark, Greenbowe Joel, Schrock Alexa B, Hezel Aram F, Ross Jeffrey S, Stephens Phillip J, Ali Siraj M, Miller Vincent A, Fakih Marwan, Klempner Samuel |
| CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients. Journal of the American Academy of Dermatology 2018 Sep . Dalmasso Bruna, Pastorino Lorenza, Ciccarese Giulia, Andreotti Virginia, Grillo Federica, Mastracci Luca, Spagnolo Francesco, Ballestrero Alberto, Queirolo Paola, Bruno William, Ghiorzo Pao |
| Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study. Journal for immunotherapy of cancer 2019 7 7 (1): 180. Forschner Andrea, Battke Florian, Hadaschik Dirk, Schulze Martin, Weißgraeber Stephanie, Han Chung-Ting, Kopp Maria, Frick Maximilian, Klumpp Bernhard, Tietze Nicola, Amaral Teresa, Martus Peter, Sinnberg Tobias, Eigentler Thomas, Keim Ulrike, Garbe Claus, Döcker Dennis, Biskup Sask |
| Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature. Journal of the National Comprehensive Cancer Network : JNCCN 2020 5 18 (5): 517-521. Chumsri Saranya, Sokol Ethan S, Soyano-Muller Aixa E, Parrondo Ricardo D, Reynolds Gina A, Nassar Aziza, Thompson E Aubr |
| Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients. Scientific reports 2020 Oct 10 (1): 17687. Aoude Lauren G, Bonazzi Vanessa F, Brosda Sandra, Patel Kalpana, Koufariotis Lambros T, Oey Harald, Nones Katia, Wood Scott, Pearson John V, Lonie James M, Arneil Melissa, Atkinson Victoria, Smithers B Mark, Waddell Nicola, Barbour Andrew |
| Impact of molecular testing in advanced melanoma on outcomes in a tertiary cancer center and as reported in a publicly available database. Cancer reports (Hoboken, N.J.) 2021 Jun e1380. Dimitrova Maya, Kim Min Jae, Osman Iman, Jour Geor |
| No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study. Cancers 2021 Jan 13 (3): . Guida Michele, Bartolomeo Nicola, Quaglino Pietro, Madonna Gabriele, Pigozzo Jacopo, Di Giacomo Anna M, Minisini Alessandro M, Tucci Marco, Spagnolo Francesco, Occelli Marcella, Ridolfi Laura, Queirolo Paola, De Risi Ivana, Quaresmini Davide, Gambale Elisabetta, Chiaron Sileni Vanna, Ascierto Paolo A, Stigliano Lucia, Strippoli Sabino, On Behalf Of The Italian Melanoma Intergroup Imi Stud |
| PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score. Cancers 2021 Sep 13 (18): . Cho Yoon Ah, Lee Hyunwoo, Kim Deok Geun, Kim Hyunjin, Ha Sang Yun, Choi Yoon-La, Jang Kee-Taek, Kim Kyoung-M |
| Melanoma-specific survival before and after inclusion in a familial melanoma dermatologic surveillance program in CDKN2A mutation carriers and non-carriers. Journal of the European Academy of Dermatology and Venereology : JEADV 2022 9 37 (2): 284-292. Pissa Maria, Lapins Jan, Sköldmark Christina, Helgadottir Hild |
| Correlation of MRI signal characteristics of intracranial melanoma metastases with BRAF mutation status. Melanoma research 2022 10 32 (5): 373-378. Lasocki Arian, McArthur Grant |
| NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma. Frontiers in immunology 2022 13 894110. Li Hongxia, Zhang Qin, Duan Qianqian, Tan Yuan, Sun Tingting, Qi Chua |
| Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy. Scientific reports 2022 Jun 12 (1): 9559. Huang Fuxue, Li Jingjing, Wen Xizhi, Zhu Baoyan, Liu Wei, Wang Jiuhong, Jiang Hang, Ding Ya, Li Dandan, Zhang Xiaos |
| Variable Genomic Landscapes of Advanced Melanomas with Heavy Pigmentation. The oncologist 2022 May . Huang Richard S P, Tse Julie Y, Harries Lukas, Graf Ryon P, Lin Douglas I, Murugesan Karthikeyan, Hiemenz Matthew C, Parimi Vamsi, Janovitz Tyler, Decker Brennan, Severson Eric, Levy Mia A, Ramkissoon Shakti H, Elvin Julia A, Ross Jeffrey S, Williams Erik |
| Genomic comparison of malignant melanoma and atypical Spitz tumor in the pediatric population. Pediatric dermatology 2022 Feb . Church Alanna J, Moustafa Danna, Pinches Robert Seth, Hawryluk Elena B, Schmidt Birgitta A |
| Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better. Journal for immunotherapy of cancer 2022 2 10 (1): . Zheng Mi |
| HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma. Aging 2023 8 15 . Liu Li, Kuang Tianrui, Li Chunlei, Qiu Zhendong, Chen Xiaoyan, Deng Wenho |
| Temporal correlation between the first melanoma and the first noncutaneous tumor in CKDN2A genotyped patients. Melanoma research 2023 6 . Laura Cristina Gironi, Elia Esposto, Francesca Zottarelli, Roberto Giorgione, Pamela Farinelli, Elisa Zavattaro, Edoardo Cammarata, Nunzia Di Cristo, Paola Ogliara, Lara Camillo, Mara Giordano, Simona Mellone, Barbara Pasini, Alessandro Ambrosi, Paola Savo |
| Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: A real-world retrospective study from single center in China. Cancer medicine 2023 4 . Zhong Jingqin, Sun Wei, Hu Tu, Wang Chunmeng, Yan Wangjun, Luo Zhiguo, Liu Xin, Xu Yu, Chen Yo |
| Utility of Tumor Mutational Burden as a Biomarker for Response to Immune Checkpoint Inhibition in the VA Population. JCO precision oncology 2023 12 7 e2300176. Micaela R Scobie, Katherine I Zhou, Sara Ahmed, Michael J Kell |
| PCDH11X mutation as a potential biomarker for immune checkpoint therapies in lung adenocarcinoma. Journal of molecular medicine (Berlin, Germany) 2024 5 . Manjiao Liu, Meijia Yang, Bei Zhang, Sijian Xia, Jie Zhao, Linlin Yan, Yong Ren, Hao Guo, Jie Zh |
| Predictive value of ZFHX4 mutation for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer and melanoma. Investigational new drugs 2024 10 . Cong Fu, Haoran Gu, Lin Sun, Zhouyu Wang, Qin Zhang, Ningning Luo, Dongsheng Chen, Tong Zh |
- Page last reviewed:Feb 1, 2024
- Content source: